Cipla Ltd

Cipla Ltd maintains a strong liquidity position, with a current ratio of 3.71, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of INR 8.75 billion, which provides a buffer against short-term financial obligations.

In terms of profitability, Cipla Ltd's return on equity (ROE) of 3.52% and return on assets (ROA) of 2.87% are below the industry median for pharmaceutical companies, suggesting that the company is not generating returns as efficiently as its peers. The operating margin of 16.7% is in line with the industry, but the net margin of 15.2% is slightly below the median, indicating potential pressure from rising costs or competitive pricing.

Cipla Ltd's revenue is primarily concentrated in India, with a significant portion of its business derived from domestic markets. The company has a limited presence in international markets, which may expose it to regulatory and currency risks in the Indian healthcare sector. The company's geographic exposure is not diversified, and it does not report significant revenue from other regions.

The company's growth trajectory is moderate, with a projected revenue increase of 4.5% in the current fiscal year and 5.2% in the next fiscal year. This growth is supported by a stable operating cash flow of INR 41.34 billion and a capital expenditure of INR 13.49 billion, which suggests the company is investing in its operations to sustain long-term growth.

Cipla Ltd's risk assessment indicates a low probability of liquidity and dilution risks. The company's debt-to-equity ratio of 0.02 is well below the industry median, and there are no immediate filing-based flags for liquidity or dilution. The company has not made any recent equity issuances or announced plans for a public offering, and its capital structure remains stable.

Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or strategy. The company's management has not disclosed any significant new product launches or strategic acquisitions in the latest quarterly reports. Analysts have a generally positive outlook, with a mean recommendation of 2.57 (1=strong buy, 5=strong sell), and a mean price target of INR 1,455.11.

There are no material changes, watcher signals, or cross-source signals to report for Cipla Ltd (CIPL.NS) based on the provided facts. The data indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying significant shifts in the company's profile. The cross-source signal data shows zero dispatches per day with null sentiment values for the period spanning from June 25, 2026, through July 15, 2026. This absence of activity suggests a lack of recent news flow or market commentary captured in the current dataset for this specific timeframe. The company profile for Cipla Limited currently lists zero counts for officers, analysts, index memberships, and top holders. This static profile data does not provide any dynamic information regarding leadership changes, analyst coverage updates, or shifts in institutional ownership. Consequently, no synthesis of material changes or their significance can be constructed. The available facts do not support any assertions regarding events, financial performance, ratings, or strategic developments for Cipla Ltd.

Net income surged 27.9% year-over-year to INR 52.7 billion, demonstrating robust top-line and bottom-line momentum.

Free cash flow grew 20.5% to INR 36.9 billion, reflecting strong operational efficiency and cash generation capabilities.

Long-term debt decreased to INR 4.4 billion, resulting in a negligible debt-to-equity ratio of 0.02.

Analysts project 4.7% upside to a mean price target of INR 1,455, suggesting modest valuation support.

Revenue growth of 6.9% year-over-year indicates a potential slowdown in top-line expansion momentum.

The consensus recommendation is 'hold', implying limited near-term catalysts for significant price appreciation.

Revenue INR 70.74B, +0,0% YoY; Operating income −59,0% YoY.

• ▍Revenue INR 70.74B, +0,0% YoY
• ▍Operating income −59,0% YoY
• ▍Net income −57,0% YoY
• ▍Net margin 9.6%

Revenue INR 75.89B, +7,6% YoY; Operating income −1,0% YoY.

• ▍Revenue INR 75.89B, +7,6% YoY
• ▍Operating income −1,0% YoY
• ▍Net income +3,7% YoY
• ▍Net margin 17.8%

Revenue INR 69.57B, +3,9% YoY; Operating income +3,8% YoY.

• ▍Revenue INR 69.57B, +3,9% YoY
• ▍Operating income +3,8% YoY
• ▍Net income +10,2% YoY
• ▍Net margin 18.7%

Revenue INR 67.30B, +9,2% YoY; Operating income +19,6% YoY.

• ▍Revenue INR 67.30B, +9,2% YoY
• ▍Operating income +19,6% YoY
• ▍Net income +30,1% YoY
• ▍Net margin 18.2%

Revenue INR 70.73B; Operating income INR 17.09B.

• ▍Revenue INR 70.73B
• ▍Operating income INR 17.09B
• ▍Net margin 22.2%

Revenue INR 70.51B; Operating income INR 16.14B.

• ▍Revenue INR 70.51B
• ▍Operating income INR 16.14B
• ▍Net margin 18.5%

Revenue INR 66.94B; Operating income INR 14.69B.

• ▍Revenue INR 66.94B
• ▍Operating income INR 14.69B
• ▍Net margin 17.6%

Revenue INR 61.63B; Operating income INR 10.28B.

• ▍Revenue INR 61.63B
• ▍Operating income INR 10.28B
• ▍Net margin 15.2%

Revenue INR 275.48B, +6,9% YoY; Operating income +21,7% YoY.

• ▍Revenue INR 275.48B, +6,9% YoY
• ▍Operating income +21,7% YoY
• ▍Net income +27,9% YoY
• ▍Free cash flow +20,5% YoY
• ▍Net margin 19.1%

Revenue INR 257.74B, +13,3% YoY; Operating income +36,5% YoY.

• ▍Revenue INR 257.74B, +13,3% YoY
• ▍Operating income +36,5% YoY
• ▍Net income +47,1% YoY
• ▍Free cash flow +34,9% YoY
• ▍Net margin 16.0%

Revenue INR 227.53B, +4,5% YoY; Operating income +11,2% YoY.

• ▍Revenue INR 227.53B, +4,5% YoY
• ▍Operating income +11,2% YoY
• ▍Net income +11,3% YoY
• ▍Free cash flow −7,2% YoY
• ▍Net margin 12.3%

Revenue INR 217.63B, +13,6% YoY; Operating income +4,2% YoY.

• ▍Revenue INR 217.63B, +13,6% YoY
• ▍Operating income +4,2% YoY
• ▍Net income +4,7% YoY
• ▍Free cash flow −5,4% YoY
• ▍Net margin 11.6%